Quantum Pharma acquisition 'the logical next step' in growth story for Clinigen

Published on 13th Sep 2017

Shaun Chilton, chief executive of Clinigen Group PLC (LON:CLIN), tells Proactive they're closing in on the acquisition of fellow AIM-listed specialty pharma Quantum Pharma PLC (LON:QP.) after the two agreed a £150mln cash-plus-shares deal.

The offer, which has been recommended by Quantum to its shareholders, will see Clinigen pay 37p in cash and 0.0405 new Clinigen shares for each Quantum share.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: